Gyre Therapeutics, Inc.
GYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001124105
No open-market purchases or sales by Gyre Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $57.1M in total; no superinvestor holds it.
Q2 2022 vs. Q1 2022
How the institutions holding Gyre Therapeutics, Inc. changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Q2 2022 | Change |
|---|---|---|---|
| Holders | 43 | 41 | −2 |
| Shares | 9.68M | 8.03M | −1.65M (−17.0%) |
| Value | $6.39M | $14.2M | +$7.81M (+122.3%) |
New holders (7)
Institutions that held Gyre Therapeutics, Inc. at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Madison Avenue Partners, LP | 1,006,300 | $1.79M | 0.37% |
| Citadel Advisors LLC | 75,880 | $135.0K | 0.00% |
| Virtu Financial LLC | 53,977 | $96.0K | 0.01% |
| Prudential Financial Inc | 20,400 | $36.0K | 0.00% |
| United Capital Financial Advisers, LLC | 10,000 | $18.0K | 0.00% |
| UBS Group AG | 7,682 | $14.0K | 0.00% |
| Citigroup Inc | 500 | $1.00K | 0.00% |
Sold out (9)
Institutions that held Gyre Therapeutics, Inc. at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Sabby Management, LLC | 1,320,000 | $871.0K |
| Ikarian Capital, LLC | 476,625 | $314.0K |
| CSS LLC | 88,656 | $59.0K |
| Dimensional Fund Advisors LP | 77,127 | $51.0K |
| D. E. Shaw & Co., Inc. | 62,368 | $41.0K |
| Two Sigma Investments, LP | 62,729 | $41.0K |
| Boothbay Fund Management, LLC | 45,915 | $30.0K |
| Gyon Technologies Capital Management, LP | 23,421 | $15.0K |
| Geneos Wealth Management Inc. | 11,000 | $7.00K |